1-(3-methyl-1H-pyrazol-1-yl)acetone | 925200-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(3-methyl-1H-pyrazol-1-yl)acetone
• 英文别名: 1-(3-methylpyrazol-1-yl)propan-2-one
• CAS: 925200-30-2
• 化学式: C₇H₁₀N₂O
• mdl: MFCD04969968
• 分子量: 138.17
• InChiKey: XDMSPPHMAZVVAT-UHFFFAOYSA-N

物化性质

• 沸点：
  228.0±23.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

文献信息

• Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence
  申请人：Gottesdiener Keith M.

  公开号：US20090270406A1

  公开（公告）日：2009-10-29

  This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-tri-fluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof. In another aspect, this invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-tri-fluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof.

  这项发明涉及用于治疗尿频、尿急和尿失禁的组合物，包括(R)-N-[4-[2-[[2-羟基-2-(吡啶-3-基)乙基]氨基]乙基]苯基]-4-[4-(4-三氟甲基苯基)噻唑-2-基]苯磺酰胺及其药学上可接受的盐。另一方面，这项发明涉及用于尿频、尿急和尿失禁的联合疗法，其中一种活性药物是(R)-N-[4-[2-[[2-羟基-2-(吡啶-3-基)乙基]氨基]乙基]苯基]-4-[4-(4-三氟甲基苯基)噻唑-2-基]苯磺酰胺及其药学上可接受的盐。
• Phenyl pyrrolidine ether tachykinin receptor antagonists
  申请人：DeVita J. Robert

  公开号：US20070043015A1

  公开（公告）日：2007-02-22

  The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, depression, and anxiety.

  本发明涉及某些苯基吡咯烷醚化合物，其作为神经激肽-1（NK-1）受体拮抗剂和快速激肽，特别是物质P的抑制剂具有用途。本发明还涉及包含这些化合物作为活性成分的制药配方以及这些化合物及其配方在治疗某些疾病，包括呕吐、抑郁和焦虑方面的应用。
• Compounds
  申请人：Alcaraz Lilian

  公开号：US20090298807A1

  公开（公告）日：2009-12-03

  The present invention relates to spirocyclic amide derivatives of the formula I, pharmaceutically acceptable salts thereof, a process for their preparation, pharmaceutical compositions containing them, and their use in therapy.

  本发明涉及公式 I 的螺环酰胺衍生物，其药学上可接受的盐，其制备方法，含有它们的制药组合物以及它们在治疗中的应用。
• FUNGICIDAL OXIMES AND HYDRAZONES
  申请人：Hanagan Mary Ann

  公开号：US20130030002A1

  公开（公告）日：2013-01-31

  Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein E, X, G, W 2 and Z are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention. Also disclosed are compounds of Formula 1A including all stereoisomers, N-oxides, and salts thereof, wherein E, X, G and Z 1 are as defined in the disclosure. Also disclosed is the use of the compounds of Formula 1A as intermediates for preparing compounds of Formula 1.

  本发明涉及公式1的化合物，包括所有立体异构体、N-氧化物和其盐，其中E、X、G、W2和Z如本公开说明书中所定义。还涉及含有公式1化合物的组合物以及控制由真菌病原体引起的植物病害的方法，包括施用本发明化合物或组合物的有效量。还涉及公式1A的化合物，包括所有立体异构体、N-氧化物和其盐，其中E、X、G和Z1如本公开说明书中所定义。还涉及将公式1A的化合物用作制备公式1化合物的中间体的用途。
• COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1937264B1

  公开（公告）日：2011-06-08